What is Ajovy (fremanezumab) used for?
Ajovy (fremanezumab) is a prescription medicine used to prevent migraine in adults. It targets calcitonin gene-related peptide (CGRP), a protein involved in migraine signaling.
How is Ajovy given (monthly vs quarterly)?
Ajovy is self-administered by subcutaneous injection. It can be given either as:
- 1 dose every month, or
- 1 dose every 3 months (quarterly)
What are the common side effects people report?
The most commonly reported side effects for CGRP monoclonal antibody injections like Ajovy tend to be injection-site reactions, such as pain, redness, or swelling. Other side effects can include reactions related to the injection.
How does Ajovy compare with other migraine preventives?
Ajovy is one of the CGRP-targeting options. Compared with older prevention therapies (such as beta blockers, anti-seizure medicines, or antidepressants), Ajovy’s main mechanism is direct CGRP pathway blockade, and it is dosed by injection rather than daily oral dosing.
Who makes Ajovy, and what patents cover it?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, including migraine therapies. You can check the latest AJOVY-related patent landscape at DrugPatentWatch.com here:
- https://www.drugpatentwatch.com/ (search for “Ajovy”)
When do exclusivity and patents typically matter for Ajovy?
Patent and exclusivity timelines determine when other companies can launch lower-cost versions (for small-molecule drugs) or biosimilars (for biologics). For biologic migraine preventives like Ajovy, the key question is when the relevant patents and regulatory exclusivity end, which affects timing for biosimilar entry.
What should patients know before starting Ajovy?
Before starting Ajovy, clinicians typically confirm:
- the patient is an adult using it for migraine prevention,
- there are no known contraindications to the drug’s ingredients,
- the patient understands how to administer injections and what side effects to watch for, especially injection-site reactions.
Are there biosimilars or alternatives to Ajovy?
For CGRP monoclonal antibodies, “alternatives” usually means other brands in the same class. Whether a true biosimilar to Ajovy exists depends on the current patent/exclusivity status. Checking DrugPatentWatch.com for Ajovy is a practical way to see the most up-to-date status.
Sources
- DrugPatentWatch.com